Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1998 Oct;89(10):1061-6.
doi: 10.1111/j.1349-7006.1998.tb00497.x.

Tumor-selective distribution of an active metabolite of the 9-aminoanthracycline amrubicin

T Noguchi  1 , S Ichii, S Morisada, T Yamaoka, Y Yanagi
Affiliations

Tumor-selective distribution of an active metabolite of the 9-aminoanthracycline amrubicin

T Noguchi et al. Jpn J Cancer Res. 1998 Oct.

Abstract

It has been reported that the 9-aminoanthracycline amrubicin shows good efficacy in human tumor xenograft models. We studied the disposition and metabolism of amrubicin in mice, in comparison with those of doxorubicin. Amrubicinol, a 13-hydroxy metabolite of amrubicin, which is 10 to 100 times more cytotoxic than amrubicin, was detected as a major metabolite in blood and tissues, and aglycones of amrubicin were also detected. A pharmacokinetic study revealed that amrubicin had a smaller distribution volume and a shorter half-life than doxorubicin. In several normal tissues, the levels of amrubicin and amrubicinol were lower than those of doxorubicin. In contrast, the tumor levels of amrubicinol in the mice treated with amrubicin were higher than those of doxorubicin in the mice treated with that drug, in tumors that are sensitive to amrubicin. These results suggest that the potent therapeutic activity of amrubicin is caused by the selective distribution of its highly active metabolite, amrubicinol, in tumors.

PubMed Disclaimer

References

    1. ) Ishizumi , K. , Ohashi , N. and Tanno , N.Stereospecific total synthesis of 9‐aminoanthracyclines: (+)‐9‐amino‐9‐deoxydaunomycin and related compounds . J. Org. Chem. , 52 , 4477 – 4485 ( 1987. ).
    1. ) Morisada , S. , Yanagi , Y. , Noguchi , T. , Kashiwazaki , Y. and Fukui , M.Antitumor activities of a novel 9‐aminoanthracycline (SM‐5887) against mouse experimental tumors and human tumor xenografts . Jpn. J. Cancer Res. , 80 , 69 – 76 ( 1989. ). - PMC - PubMed
    1. ) Yokota , S. , Negoro , S. , Yana , T. , Takada , Y. , Fukuoka , M.and The West Japan Lung Cancer Group. Phase II study of amrubicin (SM‐5887), a novel 9‐aminoanthracycline, in previously untreated patients with extensive‐stage small‐cell lung cancer (ES‐SCLC): a trial of The West Japan Lung Cancer Group . 8th World Conference on Lung Cancer , A1576 ( 1997. ).
    1. ) Hiraki , S. , Shinkai , T. , Furuse , K. , Fukuoka , M. , Ohnoshi , T. , Kimura , I.and The SM‐5887 Lung Cancer Study Group. A phase II of SM‐5887, a novel 9‐aminoanthracycline, for non‐small cell lung cancer . 18th International Congress of Chemotherapy , æ 726 ( 1993. ).
    1. ) Yesair , W. , Schwartzbach , E. , Shuck , D. , Denine , E. P. and Asbell , A.Comparative pharmacokinetics of daunomycin and adriamycin in several animal species . Cancer Res. , 32 , 1177 – 1183 ( 1972. ). - PubMed

LinkOut - more resources